Gen-Probe (US) gets Transcription Mediated Amplification (TMA) patent
This article was originally published in Clinica
Gen-Probe (US) has received a US patent for Transcription Mediated Amplification (TMA). A Mycobacterium tuberculosis test based on the technique received a conditional approval recommendation from the US FDA advisory panel on May 2nd (see this issue p 15). A urine and urogenital sample-based Chlamydia trachomatis kit will enter clinical trials in the near future and tests for HIV viral RNA, hepatitis B virus DNA and leukaemia are in development.
You may also be interested in...
Less-invasive technologies to treat benign prostatic hyperplasia are fast becoming viable alternatives to medication and surgery. Here's what one researcher in the area, Steven Raman, had to say about the new options.
Novartis’s first digital innovation hub in Asia is launched in India, where the Swiss company hopes to ally with partners to deliver digital solutions for patients at scale.
Senate Finance Committee’s approach to penalize companies for raising WAC list prices is not a ‘price control,’ but a reasonable approach to change the incentives that distort pricing in the supply chain, US HHS Secretary Alex Azar says.